10 results on '"Margherita Gaudenzi"'
Number of results to display per page
Search Results
2. Heart failure in COVID‐19: the multicentre, multinational PCHF‐COVICAV registry
- Author
-
Mateusz Sokolski, Sander Trenson, Justyna M. Sokolska, Domenico D'Amario, Philippe Meyer, Nana K. Poku, Tor Biering‐Sørensen, Mats C. Højbjerg Lassen, Kristoffer G. Skaarup, Eduardo Barge‐Caballero, Anne‐Catherine Pouleur, Davide Stolfo, Gianfranco Sinagra, Klemens Ablasser, Viktoria Muster, Peter P. Rainer, Markus Wallner, Alessandra Chiodini, Pascal S. Heiniger, Fran Mikulicic, Judith Schwaiger, Stephan Winnik, Huseyin A. Cakmak, Margherita Gaudenzi, Massimo Mapelli, Irene Mattavelli, Matthias Paul, Irina Cabac‐Pogorevici, Claire Bouleti, Marzia Lilliu, Chiara Minoia, Jeroen Dauw, Jérôme Costa, Ahmet Celik, Nathan Mewton, Carlos E.L. Montenegro, Yuya Matsue, Goran Loncar, Michal Marchel, Aris Bechlioulis, Lampros Michalis, Marcus Dörr, Edgard Prihadi, Felix Schoenrath, Daniel R. Messroghli, Wilfried Mullens, Lars H. Lund, Giuseppe M.C. Rosano, Piotr Ponikowski, Frank Ruschitzka, and Andreas J. Flammer
- Subjects
COVID‐19 ,SARS‐CoV2 ,Heart failure ,Cardiovascular disease ,Risk factors ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Abstract Aims We assessed the outcome of hospitalized coronavirus disease 2019 (COVID‐19) patients with heart failure (HF) compared with patients with other cardiovascular disease and/or risk factors (arterial hypertension, diabetes, or dyslipidaemia). We further wanted to determine the incidence of HF events and its consequences in these patient populations. Methods and results International retrospective Postgraduate Course in Heart Failure registry for patients hospitalized with COVID‐19 and CArdioVascular disease and/or risk factors (arterial hypertension, diabetes, or dyslipidaemia) was performed in 28 centres from 15 countries (PCHF‐COVICAV). The primary endpoint was in‐hospital mortality. Of 1974 patients hospitalized with COVID‐19, 1282 had cardiovascular disease and/or risk factors (median age: 72 [interquartile range: 62–81] years, 58% male), with HF being present in 256 [20%] patients. Overall in‐hospital mortality was 25% (n = 323/1282 deaths). In‐hospital mortality was higher in patients with a history of HF (36%, n = 92) compared with non‐HF patients (23%, n = 231, odds ratio [OR] 1.93 [95% confidence interval: 1.44–2.59], P
- Published
- 2021
- Full Text
- View/download PDF
3. Determinants of the protective effect of glucocorticoids on mortality in hospitalized patients with COVID-19
- Author
-
Matteo Pagnesi, Riccardo M. Inciardi, Carlo M. Lombardi, Piergiuseppe Agostoni, Pietro Ameri, Lucia Barbieri, Antonio Bellasi, Rita Camporotondo, Claudia Canale, Valentina Carubelli, Stefano Carugo, Francesco Catagnano, Laura A. Dalla Vecchia, Gian Battista Danzi, Mattia Di Pasquale, Margherita Gaudenzi, Stefano Giovinazzo, Massimiliano Gnecchi, Marco Guazzi, Annamaria Iorio, Maria Teresa La Rovere, Sergio Leonardi, Gloria Maccagni, Massimo Mapelli, Davide Margonato, Marco Merlo, Luca Monzo, Andrea Mortara, Vincenzo Nuzzi, Massimo Piepoli, Italo Porto, Andrea Pozzi, Filippo Sarullo, Gianfranco Sinagra, Chiara Tedino, Daniela Tomasoni, Maurizio Volterrani, Gregorio Zaccone, Michele Senni, and Marco Metra
- Subjects
COVID-19 ,SARS-CoV-2 ,Glucocorticoid ,Corticosteroid ,Steroid ,Infectious and parasitic diseases ,RC109-216 - Abstract
Background: Glucocorticoid therapy has emerged as an effective therapeutic option in hospitalized patients with coronavirus disease 2019 (COVID-19). This study aimed to focus on the impact of relevant clinical and laboratory factors on the protective effect of glucocorticoids on mortality. Methods: A sub-analysis was performed of the multicenter Cardio-COVID-Italy registry, enrolling consecutive patients with COVID-19 admitted to 13 Italian cardiology units between 01 March 2020 and 09 April 2020. The primary endpoint was in-hospital mortality. Results: A total of 706 COVID-19 patients were included (349 treated with glucocorticoids, 357 not treated with glucocorticoids). After adjustment for relevant covariates, use of glucocorticoids was associated with a lower risk of in-hospital mortality (adjusted HR 0.44; 95% CI 0.26–0.72; p = 0.001). A significant interaction was observed between the protective effect of glucocorticoids on mortality and PaO2/FiO2 ratio on admission (p = 0.042), oxygen saturation on admission (p = 0.017), and peak CRP (0.023). Such protective effects of glucocorticoids were mainly observed in patients with lower PaO2/FiO2 ratio (100 mg/L). Conclusions: The protective effects of glucocorticoids on mortality in COVID-19 were more evident among patients with worse respiratory parameters and higher systemic inflammation.
- Published
- 2021
- Full Text
- View/download PDF
4. Cardiac Care of Non-COVID-19 Patients During the SARS-CoV-2 Pandemic: The Pivotal Role of CCTA
- Author
-
Edoardo Conte, Saima Mushtaq, Maria Elisabetta Mancini, Andrea Annoni, Alberto Formenti, Giuseppe Muscogiuri, Margherita Gaudenzi Asinelli, Carlo Gigante, Carlos Collet, Jeroen Sonck, Marco Guglielmo, Andrea Baggiano, Nicola Cosentino, Marialessia Denora, Marta Belmonte, Cecilia Agalbato, Andrea Alessandro Esposito, Emilio Assanelli, Antonio L. Bartorelli, Mauro Pepi, Gianluca Pontone, and Daniele Andreini
- Subjects
atherosclerosis ,COVID-19 ,cardiac CT ,chest pain ,coronary artery disease ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Aim: The aim of this study is to evaluate the potential use of coronary CT angiography (CCTA) as the sole available non-invasive diagnostic technique for suspected coronary artery disease (CAD) during the coronavirus disease 2019 (COVID-19) pandemic causing limited access to the hospital facilities.Methods and Results: A consecutive cohort of patients with suspected stable CAD and clinical indication to non-invasive test was enrolled in a hub hospital in Milan, Italy, from March 9 to April 30, 2020. Outcome measures were obtained as follows: cardiac death, ST-elevation myocardial infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI), and unstable angina. All the changes in medical therapy following the result of CCTA were annotated. A total of 58 patients with a mean age of 64 ± 11 years (36 men and 22 women) were enrolled. CCTA showed no CAD in 14 patients (24.1%), non-obstructive CAD in 30 (51.7%) patients, and obstructive CAD in 14 (24.1%) patients. Invasive coronary angiography (ICA) was considered deferrable in 48 (82.8%) patients. No clinical events were recorded after a mean follow-up of 376.4 ± 32.1 days. Changes in the medical therapy were significantly more prevalent in patients with vs. those without CAD at CCTA.Conclusion: The results of the study confirm the capability of CCTA to safely defer ICA in the majority of symptomatic patients and to correctly identify those with critical coronary stenoses necessitating coronary revascularization. This characteristic could be really helpful especially when the hospital resources are limited
- Published
- 2021
- Full Text
- View/download PDF
5. Quantification of extracellular volume with cardiac computed tomography in patients with dilated cardiomyopathy
- Author
-
Andrea Baggiano, Edoardo Conte, Luigi Spiritigliozzi, Saima Mushtaq, Andrea Annoni, Maria Ludovica Carerj, Francesco Cilia, Fabio Fazzari, Alberto Formenti, Antonio Frappampina, Laura Fusini, Margherita Gaudenzi Asinelli, Daniele Junod, Maria Elisabetta Mancini, Valentina Mantegazza, Riccardo Maragna, Francesca Marchetti, Marco Penso, Luigi Tassetti, Alessandra Volpe, Francesca Baessato, Marco Guglielmo, Alexia Rossi, Chiara Rovera, Daniele Andreini, Mark G. Rabbat, Andrea Igoren Guaricci, Mauro Pepi, and Gianluca Pontone
- Subjects
Radiology, Nuclear Medicine and imaging ,Cardiology and Cardiovascular Medicine - Published
- 2023
6. Determinants of the protective effect of glucocorticoids on mortality in hospitalized patients with COVID-19
- Author
-
Margherita Gaudenzi, Riccardo M. Inciardi, Filippo M. Sarullo, Michele Senni, Matteo Pagnesi, Carlo Lombardi, Marco Metra, Antonio Bellasi, Francesco Catagnano, Gianfranco Sinagra, Laura Adelaide Dalla Vecchia, Massimiliano Gnecchi, Lucia Barbieri, Daniela Tomasoni, Annamaria Iorio, Gregorio Zaccone, Marco Guazzi, Stefano Giovinazzo, Davide Margonato, Andrea Mortara, Maurizio Volterrani, Mattia Di Pasquale, Massimo F Piepoli, Stefano Carugo, Maria Teresa La Rovere, Marco Merlo, Vincenzo Nuzzi, Andrea Pozzi, Valentina Carubelli, Sergio Leonardi, Piergiuseppe Agostoni, Italo Porto, Rita Camporotondo, Gloria Maccagni, Massimo Mapelli, Luca Monzo, Claudia Canale, Pietro Ameri, Gian Battista Danzi, and Chiara Tedino
- Subjects
0301 basic medicine ,Microbiology (medical) ,medicine.medical_specialty ,030106 microbiology ,Infectious and parasitic diseases ,RC109-216 ,Lower risk ,03 medical and health sciences ,0302 clinical medicine ,Glucocorticoid ,Fraction of inspired oxygen ,Internal medicine ,medicine ,Clinical endpoint ,Corticosteroid ,030212 general & internal medicine ,Adverse effect ,Steroid ,biology ,business.industry ,SARS-CoV-2 ,C-reactive protein ,COVID-19 ,Retrospective cohort study ,General Medicine ,Infectious Diseases ,Coronary care unit ,biology.protein ,business ,medicine.drug - Abstract
Background: Glucocorticoid therapy has emerged as an effective therapeutic option in hospitalized patients with coronavirus disease 2019 (COVID-19). This study aimed to focus on the impact of relevant clinical and laboratory factors on the protective effect of glucocorticoids on mortality. Methods: A sub-analysis was performed of the multicenter Cardio-COVID-Italy registry, enrolling consecutive patients with COVID-19 admitted to 13 Italian cardiology units between 01 March 2020 and 09 April 2020. The primary endpoint was in-hospital mortality. Results: A total of 706 COVID-19 patients were included (349 treated with glucocorticoids, 357 not treated with glucocorticoids). After adjustment for relevant covariates, use of glucocorticoids was associated with a lower risk of in-hospital mortality (adjusted HR 0.44; 95% CI 0.26–0.72; p = 0.001). A significant interaction was observed between the protective effect of glucocorticoids on mortality and PaO2/FiO2 ratio on admission (p = 0.042), oxygen saturation on admission (p = 0.017), and peak CRP (0.023). Such protective effects of glucocorticoids were mainly observed in patients with lower PaO2/FiO2 ratio (100 mg/L). Conclusions: The protective effects of glucocorticoids on mortality in COVID-19 were more evident among patients with worse respiratory parameters and higher systemic inflammation.
- Published
- 2021
7. Cardiac MRI after first episode of acute pericarditis: A pilot study for better identification of high risk patients
- Author
-
Edoardo Conte, Cecilia Agalbato, Gianfranco Lauri, Saima Mushtaq, Alessia Dalla Cia, Alice Bonomi, Marco Guglielmo, Andrea Baggiano, Margherita Gaudenzi-Asinelli, Gualtiero Colombo, Chiarella Sforza, Piergiuseppe Agostoni, Gloria Tamborini, Emilio Assanelli, Gianluca Pontone, Mauro Pepi, Antonio Brucato, and Daniele Andreini
- Subjects
Inflammation ,Pericarditis, Constrictive ,Contrast Media ,Humans ,Pericarditis ,Gadolinium ,Pilot Projects ,Cardiology and Cardiovascular Medicine ,Magnetic Resonance Imaging - Abstract
Cardiac magnetic resonance (CMR) was proposed as an accurate non-invasive tool to evaluate pericardial inflammation. Aim of the present study was to evaluate the role of CMR early in the course of the first episode of acute pericarditis.A clinical registry of consecutive patients who underwent clinical indicated CMR due to pericardial disease from January 2014 to January 2020 was screened. We analyzed patients with the clinical diagnosis of first episode of acute pericarditis needing hospitalization less than 7 days before CMR. Outcome measures were obtained using a single combined end-point, defined as pericardial event, including all the following: recurrent pericarditis, chronic constrictive pericarditis, surgery for pericardial disease.Twenty-six patients meet the study criteria and were enrolled. A mean follow-up of 34 ± 7 months was obtained and a second episode of pericardial event were recorded in 9 patients. At multivariate analysis adjusted for propensity score, based on clinical significative variable (younger age and higher CRP) the association between pericardial inflammation identified by CMR (positive late gadolinium enhancement on pericardium) and recurrence of pericardial events was confirmed [OR (95%CI) 8.94 (1.74-45.80), p = 0.008].Pericardial inflammation identified by CMR, with LGE images, has a prognostic value independently from clinical and bio-humoral variables.
- Published
- 2021
8. Heart failure in COVID-19: the multicentre, multinational PCHF-COVICAV registry
- Author
-
Nathan Mewton, Tor Biering-Sørensen, Marcus Dörr, Andreas J. Flammer, Michał Marchel, Wilfried Mullens, Domenico D'Amario, Yuya Matsue, Huseyin A. Cakmak, Gianfranco Sinagra, Davide Stolfo, Kristoffer Grundtvig Skaarup, Claire Bouleti, Marzia Lilliu, Felix Schoenrath, Edgard Prihadi, Irene Mattavelli, Justyna M. Sokolska, Carlos Eduardo Lucena Montenegro, Daniel Messroghli, Anne-Catherine Pouleur, Frank Ruschitzka, Matthias Paul, Nana K. Poku, Lampros K. Michalis, Mateusz Sokolski, Jérôme Costa, Alessandra Chiodini, Viktoria Muster, Jeroen Dauw, Goran Loncar, Peter P. Rainer, Philippe Meyer, Eduardo Barge-Caballero, Massimo Mapelli, Aris Bechlioulis, Fran Mikulicic, Ahmet Çelik, Piotr Ponikowski, Klemens Ablasser, Chiara Minoia, Judith Schwaiger, Sander Trenson, Markus Wallner, Lars Lund, Giuseppe M.C. Rosano, P S Heiniger, Mats Christian Højbjerg Lassen, Margherita Gaudenzi, Irina Cabac-Pogorevici, Stephan Winnik, University of Wrocław [Poland] (UWr), University hospital of Zurich [Zurich], Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven), Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Geneva University Hospital (HUG), Herlev and Gentofte Hospital, University of Copenhagen = Københavns Universitet (UCPH), Complejo Hospitalario Universitario A Coruña [A Coruña, Spain] (CHUAC), Instituto de Investigación Biomédica de A Coruña [La Corogne, Espagne] (INIBIC), A Coruña University Hospital [La Corogne, Espagne], Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares [Spain] (CIBERCV), Cliniques universitaires St Luc [Bruxelles], Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain = Catholic University of Louvain (UCL), Università degli studi di Trieste = University of Trieste, Medical University of Graz, Temple University [Philadelphia], Pennsylvania Commonwealth System of Higher Education (PCSHE), Center for Biomarker Research in Medicine [Graz, Austria] (CBmed GmbH), Mustafakemalpasa State Hospital [Bursa, Turkey] (MSH), Centro Cardiologico Monzino [Milano], Dpt di Scienze Cliniche e di Comunità [Milano] (DISCCO), Università degli Studi di Milano = University of Milan (UNIMI)-Università degli Studi di Milano = University of Milan (UNIMI)-Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), Università degli Studi di Milano = University of Milan (UNIMI), Johns Hopkins University Applied Physics Laboratory [Laurel, MD] (APL), Luzerner Kantonsspital [Lucerne, Switzerland] (LUKS), University Nicolae Testemitanu [Kishinev, Moldova] (UNT), CIC - Poitiers, Université de Poitiers-Centre hospitalier universitaire de Poitiers (CHU Poitiers)-Direction Générale de l'Organisation des Soins (DGOS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hospital 'Magalini' Villafranca - ULSS 9 Scaligera [Verona, Italy], Public Health Company Valle Olona [Busto Arsizio, Italy] (PHCVO), Ziekenhuis Oost-Limburg (ZOL), Hasselt University (UHasselt), Centre Hospitalier Universitaire de Reims (CHU Reims), Mersin University, Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Hôpital Louis Pradel [CHU - HCL], Hospices Civils de Lyon (HCL), Centre d'Investigation Clinique [Bron] (CIC1407), Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupement Hospitalier Est [Bron], Universidade Federal de Pernambuco [Recife] (UFPE), Juntendo University Hospital [Tokyo], Institute for Cardiovascular Diseases Dedinje [Belgrade, Serbia] (IC2D), University of Belgrade [Belgrade], Medical University of Warsaw - Poland, University Hospital of Ioannina, University of Medicine Greifswald, German Center for Cardiovascular Research (DZHK), Berlin Institute of Health (BIH), ZNA Heart Centre [Antwerp, Belgium], German Heart Institute Berlin [Berlin, Germany] (GHIB), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Deutsches Herzzentrum Berlin, Karolinska Institute, Karolinska University Hospital [Stockholm], IRCCS San Raffaele [Rome, Italy], Wrocław Medical University, CarMeN, laboratoire, UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - (SLuc) Service de cardiologie, Mapelli, Massimo/0000-0001-9985-7407, celik, Ahmet/0000-0002-9417-7610, Sokolski, Mateusz/0000-0001-9925-3566, Sokolska, Justyna/0000-0002-4759-5879, Lassen, Mats/0000-0002-2255-582X, Skaarup, Kristoffer/0000-0002-2690-7511, Sokolski, Mateusz, Trenson, Sander, Sokolska, Justyna M., D'Amario, Domenico, Meyer, Philippe, Poku, Nana K., Biering-Sorensen, Tor, Lassen, Mats C. Hojbjerg, Skaarup, Kristoffer G., Barge-Caballero, Eduardo, Pouleur, Anne-Catherine, Stolfo, Davide, Sinagra, Gianfranco, Ablasser, Klemens, Muster, Viktoria, Rainer, Peter P., Wallner, Markus, Chiodini, Alessandra, Heiniger, Pascal S., Mikulicic, Fran, Schwaiger, Judith, Winnik, Stephan, Cakmak, Huseyin A., Gaudenzi, Margherita, Mapelli, Massimo, Mattavelli, Irene, Paul, Matthias, Cabac-Pogorevici, Irina, Bouleti, Claire, Lilliu, Marzia, Minoia, Chiara, DAUW, Jeroen, Costa, Jerome, Celik, Ahmet, Mewton, Nathan, Montenegro, Carlos E. L., Matsue, Yuya, Loncar, Goran, Marchel, Michal, Bechlioulis, Aris, Michalis, Lampros, Dorr, Marcus, Prihadi, Edgard, Schoenrath, Felix, Messroghli, Daniel R., MULLENS, Wilfried, Lund, Lars H., Rosano, Giuseppe M. C., Ponikowski, Piotr, Ruschitzka, Frank, and Flammer, Andreas J.
- Subjects
Male ,Cardiac & Cardiovascular Systems ,[SDV]Life Sciences [q-bio] ,Disease ,030204 cardiovascular system & hematology ,0302 clinical medicine ,Interquartile range ,Original Research Articles ,Clinical endpoint ,Original Research Article ,Hospital Mortality ,Registries ,030212 general & internal medicine ,Incidence (epidemiology) ,Cardiovascular disease ,3. Good health ,[SDV] Life Sciences [q-bio] ,Female ,Cardiology and Cardiovascular Medicine ,Life Sciences & Biomedicine ,medicine.medical_specialty ,SARS‐CoV2 ,Heart failure ,CORONAVIRUS DISEASE 2019 ,SARS-CoV2 ,03 medical and health sciences ,COVID‐19 ,Diabetes mellitus ,Internal medicine ,medicine ,Diseases of the circulatory (Cardiovascular) system ,Humans ,Aged ,Retrospective Studies ,Heart Failure ,Science & Technology ,SARS-CoV-2 ,business.industry ,COVID-19 ,Odds ratio ,medicine.disease ,Confidence interval ,Risk factors ,RC666-701 ,Settore MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARE ,Cardiovascular System & Cardiology ,INHIBITORS ,business - Abstract
AIMS: We assessed the outcome of hospitalized coronavirus disease 2019 (COVID-19) patients with heart failure (HF) compared with patients with other cardiovascular disease and/or risk factors (arterial hypertension, diabetes, or dyslipidaemia). We further wanted to determine the incidence of HF events and its consequences in these patient populations. METHODS AND RESULTS: International retrospective Postgraduate Course in Heart Failure registry for patients hospitalized with COVID-19 and CArdioVascular disease and/or risk factors (arterial hypertension, diabetes, or dyslipidaemia) was performed in 28 centres from 15 countries (PCHF-COVICAV). The primary endpoint was in-hospital mortality. Of 1974 patients hospitalized with COVID-19, 1282 had cardiovascular disease and/or risk factors (median age: 72 [interquartile range: 62-81] years, 58% male), with HF being present in 256 [20%] patients. Overall in-hospital mortality was 25% (n = 323/1282 deaths). In-hospital mortality was higher in patients with a history of HF (36%, n = 92) compared with non-HF patients (23%, n = 231, odds ratio [OR] 1.93 [95% confidence interval: 1.44-2.59], P
- Published
- 2021
9. Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID-19. Results of the Cardio-COVID-Italy multicentre study
- Author
-
Gloria Maccagni, Stefano Giovinazzo, Filippo M. Sarullo, Piergiuseppe Agostoni, Massimo F Piepoli, Marco Metra, Vincenzo Nuzzi, Luca Monzo, Maria Teresa La Rovere, Margherita Gaudenzi, Andrea Pozzi, Massimo Mapelli, Claudia Canale, Lucia Barbieri, Italo Porto, Valentina Carubelli, Gian Battista Danzi, Andrea Mortara, Chiara Tedino, Marco Merlo, Gianfranco Sinagra, Marco Guazzi, Annamaria Iorio, Antonio Bellasi, Francesco Catagnano, Laura Adelaide Dalla Vecchia, Riccardo M. Inciardi, Carlo Lombardi, Daniela Tomasoni, Stefano Carugo, Mattia Di Pasquale, Maurizio Volterrani, Massimiliano Gnecchi, Gregorio Zaccone, Michele Senni, Davide Margonato, Pietro Ameri, Rita Camporotondo, Sergio Leonardi, Tomasoni, D, Inciardi, R, Lombardi, C, Tedino, C, Agostoni, P, Ameri, P, Barbieri, L, Bellasi, A, Camporotondo, R, Canale, C, Carubelli, V, Carugo, S, Catagnano, F, Dalla Vecchia, L, Danzi, G, Di Pasquale, M, Gaudenzi, M, Giovinazzo, S, Gnecchi, M, Iorio, A, La Rovere, M, Leonardi, S, Maccagni, G, Mapelli, M, Margonato, D, Merlo, M, Monzo, L, Mortara, A, Nuzzi, V, Piepoli, M, Porto, I, Pozzi, A, Sarullo, F, Sinagra, G, Volterrani, M, Zaccone, G, Guazzi, M, Senni, M, and Metra, M
- Subjects
Male ,Comorbidity ,030204 cardiovascular system & hematology ,Severity of Illness Index ,0302 clinical medicine ,Adrenal Cortex Hormones ,Interquartile range ,COVID-19 ,Heart failure ,Outcome ,SARS-CoV-2 Infection ,Acute Disease ,Age Factors ,Aged ,Aged, 80 and over ,Anticoagulants ,Blood Gas Analysis ,Chronic Disease ,Disease Progression ,Female ,Heart Failure ,Heparin ,Humans ,Italy ,Length of Stay ,Middle Aged ,Multiple Organ Failure ,Multivariate Analysis ,Partial Pressure ,Prognosis ,Proportional Hazards Models ,Protective Factors ,SARS-CoV-2 ,Sepsis ,Hospital Mortality ,Fraction of inspired oxygen ,heart failure ,outcome ,acute disease ,adrenal cortex hormones ,age factors ,aged ,aged, 80 and over ,anticoagulants ,blood gas analysis ,chronic disease ,comorbidity ,disease progression ,female ,heparin ,humans ,italy ,length of stay ,male ,middle aged ,multiple organ failure ,multivariate analysis ,partial pressure ,prognosis ,proportional hazards models ,protective factors ,sepsis ,severity of illness index ,hospital mortality ,80 and over ,Oxygen saturation (medicine) ,Hazard ratio ,Cardiology and Cardiovascular Medicine ,medicine.medical_specialty ,03 medical and health sciences ,Internal medicine ,medicine ,business.industry ,Proportional hazards model ,medicine.disease ,Confidence interval ,business - Abstract
Aims: To assess the prognostic value of a history of heart failure (HF) in patients with coronavirus disease 2019 (COVID-19). Methods and results: We enrolled 692 consecutive patients admitted for COVID-19 in 13 Italian cardiology centres between 1 March and 9 April 2020. Mean age was 67.4± 13.2 years, 69.5% of patients were males, 90 (13.0%) had a history of HF, median hospitalization length was 14 days (interquartile range 9–24). In-hospital death occurred in 37 of 90 patients (41.1%) with HF history vs. 126 of those with no HF history (20.9%). The increased risk of death associated with HF history remained significant after adjustment for clinical variables related to COVID-19 and HF severity, including comorbidities, oxygen saturation, lymphocyte count and plasma troponin [adjusted hazard ratio (HR) for death: 2.25; 95% confidence interval (CI) 1.26–4.02; P= 0.006 at multivariable Cox regression model including 404 patients]. Patients with a history of HF also had more in-hospital complications including. acute HF (33.3% vs. 5.1%, P< 0.001), acute renal failure (28.1% vs. 12.9%, P< 0.001), multiorgan failure (15.9% vs. 5.8%, P= 0.004) and sepsis (18.4% vs. 8.9%, P= 0.006). Other independent predictors of outcome were age, sex, oxygen saturation and oxygen partial pressure at arterial gas analysis/fraction of inspired oxygen ratio (PaO2/FiO2). In-hospital treatment with corticosteroids and heparin had beneficial effects (adjusted HR for death: 0.46; 95% CI 0.29–0.74; P= 0.001; n= 404 for corticosteroids, and adjusted HR 0.41; 95% CI 0.25–0.67; P< 0.001; n= 364 for heparin). Conclusions: Hospitalized patients with COVID-19 and a history of HF have an extremely poor outcome with higher mortality and in-hospital complications. HF history is an independent predictor of increased in-hospital mortality.
- Published
- 2020
10. Role of impaired iron transport on exercise performance in heart failure patients.
- Author
-
Campodonico, Jeness, Junod, Daniele, Carulli, Ermes, Russo, Gerardo Lo, Asinelli, Margherita Gaudenzi, Doni, Francesco, Bonomi, Alice, and Agostoni, Piergiuseppe
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.